Catalog No.: PC-38342Not For Human Use, Lab Use Only.
Aumolertinib (HS-10296) is a novel, third-generation EGFR tyrosine kinase inhibitor (EGFR TKI) that targets both EGFR-sensitizing and T790M resistance mutations with IC50 of 0.37 nM (T790M), 0.21 nM (del19/T790M), 0.29 nM(L858R/T790M), and 3.39 nM (EGFR WT).
Aumolertinib (HS-10296) is a novel, third-generation EGFR tyrosine kinase inhibitor (EGFR TKI) that targets both EGFR-sensitizing and T790M resistance mutations with IC50 of 0.37 nM (T790M), 0.21 nM (del19/T790M), 0.29 nM(L858R/T790M), and 3.39 nM (EGFR WT).
In cell-based assays, almonertinib inhibits EGFR phosphorylation at IC50 of 3.3 nM in HCC827 (EGFR del19) cell line, IC50 of 4.1 nM in PC9 (EGFR del19) cell line, IC50 of 3.3 nM in NCI-H1975 (EGFR L858R/T790M) cell line, but only IC50 of 596.6 nM in A431 (EGFR WT) cell line.
